Bordetella parapertussis evolved in a host population that had already developed immunity to "B. pertussis", where being able to evade "B. pertussis" immunity was an advantage. Two lineages of "B. parapertussis" have been described. The first infects humans and is responsible for a minority of cases of the disease pertussis (also known as whooping cough). The second, ovine, lineage causes chronic nonprogressive pneumonia in sheep. Both lineages are thought to have evolved from a "B. bronchiseptica"-like ancestor. This disease can be symptomatic or asymptomatic and may predispose hosts to secondary infection. Bordetella parapertussis Bordetella parapertussis is a small Gram-negative bacterium of the
Peripheral artery disease )Trial. In 2011, pCMV-vegf165 was registered in Russia as the first-in-class gene therapy drug for treatment of PAD, including the advanced stage of critical limb ischemia. Peripheral artery disease Peripheral artery disease (PAD) is an abnormal narrowing of arteries other than those that supply the heart or brain. When narrowing occurs in the heart, it is called coronary artery disease, and in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication.